Buscar
01/01/2022
The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations
Kanda, J, Hayashi, H, Ruggeri, A, Kimura, F, Volt, F, Takahashi, S, Kako, S, Tozatto-Maio, K, Yanada, M, Sanz, G, Uchida, N, Angelucci, E, Kato, S, Mohty, M, Forcade, E, Tanaka, M, Sierra, J, Ohta, T, Saccardi, R, Fukuda, T, Ichinohe, T, Kimura, T, Rocha, V, Okamoto, S, Nagler, A, Atsuta, Y, Gluckman, E. The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. BONE MARROW TRANSPLANTATION. 2022; 57(1)DOI:10.1038/s41409-021-01479-4. PMID:34635798. IF:4.800(Q1/2D).
01/01/2022
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results
Rucker, FG, Du, L, Luck, TJ, Benner, A, Krzykalla, J, Gathmann, I, Voso, MT, Amadori, S, Prior, TW, Brandwein, JM, Appelbaum, FR, Medeiros, BC, Tallman, MS, Savoie, L, Sierra, J, Pallaud, C, Sanz, MA, Jansen, JH, Niederwieser, D, Fischer, T, Ehninger, G, Heuser, M, Ganser, A, Bullinger, L, Larson, RA, Bloomfield, CD, Stone, RM, Dohner, H, Thiede, C, Dohner, K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. LEUKEMIA. 2022; 36(1)DOI:10.1038/s41375-021-01323-0. PMID:34316017. IF:11.400(Q1/1D).
01/01/2022
A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model
Pallares, V, Unzueta, U, Falgas, A, Avino, A, Nunez, Y, Garcia-Leon, A, Sanchez-Garcia, L, Serna, N, Gallardo, A, Alba-Castellon, L, Alamo, P, Sierra, J, Cedo, L, Eritja, R, Villaverde, A, Vazquez, E, Casanova, I, Mangues, R. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. BIOMATERIALS. 2022; 280DOI:10.1016/j.biomaterials.2021.121258. PMID:34847435. IF:14.000(Q1/1D).
01/01/2022
Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT
Mikulska, M, Knelange, N, Nicolini, LA, Tridello, G, Santarone, S, Di Bartolomeo, P, de la Camara, R, Cuellar, C, Velardi, A, Perruccio, K, Ljungman, P, Zaucha, J, Piekarska, A, Basak, G, Karakulska-Prystupiuk, E, Angelucci, E, Ciceri, F, Lupo-Stanghellini, MT, Fouillard, L, Garcia-Cadenas, I, Menconi, M, Blau, IW, Nassi, L, Cesaro, S, Styczynski, J. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT. JOURNAL OF INFECTION. 2022; 84(1)DOI:10.1016/j.jinf.2021.10.024. PMID:34757138. IF:28.200(Q1/1D).